Arcutis Biotherapeutics
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 2016-01-06
- Employees
- 296
- Market Cap
- $1.2B
- Website
- http://www.arcutis.com
- Introduction
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.
Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema
- Conditions
- Interventions
- First Posted Date
- 2020-05-07
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Arcutis Biotherapeutics, Inc.
- Target Recruit Count
- 230
- Registration Number
- NCT04378569
- Locations
- π¨π¦
Arcutis Clinical Site 103, London, Ontario, Canada
π¨π¦Arcutis Clinical Site 241, Richmond Hill, Ontario, Canada
π¨π¦Arcutis Clinical Site 109, Peterborough, Ontario, Canada
Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
- First Posted Date
- 2020-02-27
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Arcutis Biotherapeutics, Inc.
- Target Recruit Count
- 333
- Registration Number
- NCT04286607
- Locations
- πΊπΈ
Arcutis Biotherapeutics Clinical Site 508, Los Angeles, California, United States
πΊπΈArcutis Biotherapeutics Clinical Site 135, Pittsburgh, Pennsylvania, United States
πΊπΈArcutis Biotherapeutics Clinical Site 238, Houston, Texas, United States
Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque Psoriasis
- First Posted Date
- 2020-02-20
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- Arcutis Biotherapeutics, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT04279119
- Locations
- πΊπΈ
Arcutis Clinical Site 09, Rogers, Arkansas, United States
πΊπΈArcutis Clinical Site 02, Plainfield, Indiana, United States
πΊπΈArcutis Clinical Site 11, Fountain Valley, California, United States
Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2019-12-26
- Last Posted Date
- 2022-12-07
- Lead Sponsor
- Arcutis Biotherapeutics, Inc.
- Target Recruit Count
- 442
- Registration Number
- NCT04211389
- Locations
- πΊπΈ
Arcutis Biotherapeutics Clinical Site 203, Scottsdale, Arizona, United States
πΊπΈArcutis Biotherapeutics Clinical Site 215, Santa Monica, California, United States
πΊπΈArcutis Biotherapeutics Clinical Site 239, Beverly Hills, California, United States
Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2019-12-26
- Last Posted Date
- 2022-12-07
- Lead Sponsor
- Arcutis Biotherapeutics, Inc.
- Target Recruit Count
- 439
- Registration Number
- NCT04211363
- Locations
- πΊπΈ
Arcutis Biotherapeutics Clinical Site 135, Pittsburgh, Pennsylvania, United States
πΊπΈArcutis Biotherapeutics Clinical Site 114, Plainfield, Illinois, United States
πΊπΈArcutis Biotherapeutics Clinical Site 118, Delray Beach, Florida, United States
Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate Eczema
- Conditions
- Interventions
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Arcutis Biotherapeutics, Inc.
- Target Recruit Count
- 101
- Registration Number
- NCT04156191
- Locations
- πΊπΈ
Arcutis Clinical Site 05, Hialeah, Florida, United States
πΊπΈArcutis Clinical Site 06, San Antonio, Texas, United States
πΊπΈArcutis Clinical Site 11, Rancho Santa Margarita, California, United States
Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- Arcutis Biotherapeutics, Inc.
- Target Recruit Count
- 304
- Registration Number
- NCT04128007
- Locations
- πΊπΈ
Arcutis Biotherapeutics Clinical Site 91, Boynton Beach, Florida, United States
πΊπΈArcutis Biotherapeutics Clinical Site 71, Rogers, Arkansas, United States
πΊπΈArcutis Biotherapeutics Clinical Site 79, Covington, Louisiana, United States
Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2019-09-17
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Arcutis Biotherapeutics, Inc.
- Target Recruit Count
- 226
- Registration Number
- NCT04091646
- Locations
- πΊπΈ
Arcutis Biotherapeutics Clinical Site 40, Clinton Township, Michigan, United States
πΊπΈArcutis Biotherapeutics Clinical Site 29, Portland, Oregon, United States
πΊπΈArcutis Biotherapeutics Clinical Site 11, Austin, Texas, United States
Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2023-02-13
- Lead Sponsor
- Arcutis Biotherapeutics, Inc.
- Target Recruit Count
- 136
- Registration Number
- NCT03916081
- Locations
- πΊπΈ
Arcutis Clinical Site 20, Murfreesboro, Tennessee, United States
πΊπΈArcutis Clinical Site 03, Fridley, Minnesota, United States
π¨π¦Arcutis Clinical Site 10, Richmond Hill, Ontario, Canada
Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis
- First Posted Date
- 2018-12-05
- Last Posted Date
- 2022-09-02
- Lead Sponsor
- Arcutis Biotherapeutics, Inc.
- Target Recruit Count
- 332
- Registration Number
- NCT03764475
- Locations
- π¨π¦
Arcutis Clinical Site 11, Surrey, British Columbia, Canada
π¨π¦Arcutis Clinical Site 25, London, Ontario, Canada
πΊπΈArcutis Clinical Site 35, Beverly Hills, California, United States